Research analysts at StockNews.com assumed coverage on shares of Quotient (NASDAQ:QTNT – Get Rating) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the stock.
Separately, The Goldman Sachs Group dropped their price target on Quotient from $3.00 to $1.50 and set a “neutral” rating on the stock in a research report on Tuesday, April 19th.
Shares of QTNT opened at $0.36 on Tuesday. The business’s 50 day moving average price is $0.50 and its 200-day moving average price is $1.23. Quotient has a 52 week low of $0.27 and a 52 week high of $4.45. The stock has a market cap of $36.94 million, a P/E ratio of -0.27 and a beta of 2.72.
About Quotient (Get Rating)
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening.
- Get a free copy of the StockNews.com research report on Quotient (QTNT)
- Ride Out The Recession With These Dividend Kings
- MarketBeat: Week in Review 6/13 – 6/17
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.